Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: Malls, restaurants and streets in Daegu, the country’s fourth largest city with a population of 2.5 million, were largely empty in scenes that residents and social media users likened to a disaster movie. “It’s like someone dropped a bomb in the middle of the city. It looks like a zombie apocalypse,” Kim Geun-woo, a 28-year-old resident told Reuters by telephone. “Even Dongseong-ro Street – the most crowded centre of the city – is empty,” he said, adding that he had tried to buy surgical masks but shops were sold out. Korea’s Centres for Disease Control and Prevention (KCDC) reported 53 new cases of the virus on Thursday, following 20 a day earlier, taking the total across the country to 104. Of that national tally, 70 patients are from Daegu or nearby and the majority have been traced to an infected 61-year-old woman known as “Patient 31” who attended a church, a scenario that KCDC described as a “super-spreading event”. South Korea also reported the first death of a coronavirus patient, though the man’s exact cause of death was being investigated. The man was among 13 people at a hospital near Daegu who tested positive for the virus. Health officials said they were investigating whether there were links between the outbreak at the church and the hospital. The hospital would be temporarily shut down and about 600 staff and patients would be tested for the virus, Yonhap news agency reported, citing officials. Several major department stores, including at least one in Seoul, were closed after reports that Patient 31 had visited in recent weeks, Yonhap reported. Daegu Mayor Kwon Young-jin told residents to stay indoors as he warned of likely further cases. “We are in an unprecedented crisis,” he said at a briefing in the city, about 240 km (150 miles) southwest of the capital Seoul. Kwon cautioned that at least 90 more of the about 1,000 other people who attended services at the Temple of the Tabernacle of the Testimony were also showing symptoms. “We plan to test all believers of that church and have asked them to stay at home isolated from their families,” Kwon said. South Korea’s vice health minister Kim Kang-lip said at a separate briefing in the administrative city of Sejong that the situation was “very grave”. The cases previously reported in South Korea had mostly involved people who had travelled individually to China or come into contact with somebody who had, but it is unclear how Patient 31 contracted the virus. Daegu authorities ordered the shutdown of all kindergartens, while all schools will postpone the beginning of the spring semester scheduled for early March by one week in an unprecedented move, Yonhap said. The Defence Ministry banned troops stationed in Daegu from leaving their barracks and receiving guests, while a soldier who had recently visited his home in Daegu tested positive for the virus. The U.S. military imposed similar restrictions on its army base in the city, which houses thousands of troops, family members and civilian employees, curbing travel and closing schools and child-care centres. Media footage showed the few people on Daegu’s usually bustling downtown streets wore face masks and kept far apart. Topics such as “Daegu lockdown” and “Daegu church” were among the top searches on major South Korean portal Naver as debate heated up online about whether the city should be sealed off from the rest of the country. A KCDC official told Reuters the government was not considering that measure. The church at the centre of the outbreak is a branch of the Shincheonji Church of Jesus, a religious movement founded in 1984 by South Korean Lee Man-hee who has about 500,000 followers. Some commentators on social media blamed the custom of churchgoers sitting on the floor close to each other during services as increasing the risk of spreading the virus. Shincheonji said on Wednesday it had closed its Daegu church and instructed that services elsewhere be held online or individually at home. Claim: 'Like a zombie apocalypse': Residents on edge as coronavirus cases surge in South Korea.
Example Output: Residents of a South Korean city at the centre of a new coronavirus outbreak described empty streets, deserted shops, and a climate of fear as a surge in confirmed cases linked to a church raised the prospect of wider transmission.

Example Input: Paragraph: Most Americans are familiar with the exploits of John Glenn, a former U.S. Marine Corps pilot who, as one of the original Mercury 7 astronauts, was transformed into a national hero after becoming the first American to orbit the Earth on 20 February 1962. Later in life he represented Ohio in the United States Senate for twenty-four years, and in 1998 he became the oldest person to go into space when he flew on a Space Shuttle Discovery mission in 1998. Much less well known is John Glenn’s wife, the former Annie Castor, whom Glenn had known since childhood and married when he was a 21-year-old combat pilot during World War II. In February 2012, the fiftieth anniversary of Glenn’s orbital flight prompted CNN contributor Bob Greene to pen the article referenced above about the Glenns’ lengthy marriage (currently 68 years) and Annie’s long battle to overcome a terrible stuttering problem which had she had struggled with since she was a little girl, an affliction she finally managed to overcome at the age of 53. Annie Glenn began speaking out publicly about her lifelong struggle with her speech impediment in the early 1980s, discussing the subject on national television and in the press, crowning her achievement by making speeches on behalf of her husband as he campaigned for the 1984 Democratic presidential nomination. A 1982 Los Angeles Times article on the subject of Annie Glenn’s speaking out about her disability reported that: Annie Glenn is one of the country’s estimated 2 million people who suffer what may be the most misunderstood disability: stuttering. Until she underwent a new form of intensive, live-in treatment three years ago at the Communications Research Institute at Hollins College in Roanoke, Va., Mrs. Glenn could not speak well enough to call the plumber, order a meal in a restaurant or go by herself with her injured child to a hospital emergency room, much less give a campaign speech for her husband. Although she still stutters slightly and speaks haltingly, Mrs. Glenn can perform all those once impossible tasks. She even gives campaign speeches, maybe not with as much polish as other wives, but certainly with more pluck. At a private athletic club in Cleveland, 150 people attending the annual meeting of the Cleveland Hearing and Speech Center sat in silent attention at their dinner tables as their speaker told them something really quite remarkable. “For the first time in my life,” said Annie Glenn, age 62, “I can carry on a conversation.” It wasn’t so long ago that Mrs. Glenn, classified as an 85% stutterer, would have found it impossible, even, to travel by airplane from Washington to Cleveland by herself unless she wrote down what she wanted for the airline employee at the ticket counter. She told the audience of such an experience and how the men wrote notes back, thinking she was deaf. During the slow, agonizing process in which stutterers try to force out sounds, often with their hearts beating at an accelerated rate, their palms sweating, their cheeks blushing and their heads bobbing, Mrs. Glenn has been laughed at. Store clerks have reacted by pointing an index finger at the head and moving it in circles (the “crazy” sign), or by asking if she were cold when her jaw would quiver, or saying quite simply, “Lady, I haven’t got all day.” Sometimes Mrs. Glenn would walk away rather than continue the ordeal of shopping. Her husband had to make all the telephone calls to repairmen and friends. Her neighbors had to call the doctor when her children became ill and go to the hospital with her to talk with the doctors. Mrs. Glenn had undergone several traditional speech therapies but experienced little or no improvement until she enrolled herself for two different sessions at the Hollins Institute, most recently in September of 1978. The therapy lasts 11 hours a day for three weeks. After taking the therapy twice, Mrs. Glenn still sees a therapist twice a month at Walter Reed Hospital in Washington, and she practices every day — on the telephone. She makes several calls every morning. There is a sign next to her phone at home that says “Take a full breath, relax your throat, keep the sound moving.” “She talks to her buddies all over the world,” John Glenn said, pretending to resent the phone bills. “This is a dramatic, new life for her.” A 1983 Associated Press article on the same subject read (in part): For 53 of her 63 years, Annie Glenn was a prisoner of her own tongue, a stutterer who tripped over eight out of every 10 words, relying on facial expressions to make a point. She disciplined her two children, she recalls, “with my eyes and my hand.” Today, the wife of Ohio Sen. John Glenn has broken through a sound barrier. “Being able to talk to people is something I could never do,” she says. “My life is like a dream.” In numerous conversations [on the campaign trail] throughout a day that started before dawn and ended long after sunset, [the couple] talked about Mrs. Glenn’s newly acquired ability to speak fluently and the impact of her lifetime of stuttering on their marriage, children and career. “John would make all my telephone calls,” Mrs. Glenn says, shooting a stern look at her husband as he reached for a third chocolate bar. “I would try to go shopping but couldn’t ask the clerk what I wanted, so I would hunt and hunt. A lot of the time I’d go out of the store empty-handed because I couldn’t find what I wanted.” It was in 1974, after Mrs. Glenn enrolled in a speech program at Hollins College near Roanoke, Va., that her speech improved noticeably. But she didn’t keep up the daily therapy sessions or return for refresher courses, and she regressed. After a second session at Hollins and a program of daily therapy, Mrs. Glenn is making speeches. Claim: Article details efforts of John Glenn's wife to overcome stuttering.
Example Output: “Annie was never silent to me,” [Glenn] says. “But to see her at this age branch out to things she was interested in but could never participate in …”

Example Input: Paragraph: Developed by Eli Lilly and Co’s (LLY.N) Loxo Oncology and marketed by German drugmaker Bayer (BAYGn.DE), it fights a rare genetic mutation that appears in less than 1% of solid tumors, regardless of where they appear in the body. Finding those patients will require widespread adoption of sophisticated tests that look for multiple genetic alterations that could be driving the cancer. So far, progress has been slow. Adoption of so-called next-generation sequencing (NGS) tests has been stalled by lack of reimbursement from insurers over concerns that the evidence is not there yet to support widescale use, according to more than a dozen interviews with oncologists and pharmaceutical and diagnostic industry executives. As a result, pharma companies from small biotech Blueprint Medicines Corp (BPMC.O) to larger rivals Lilly and Roche Holding AG (ROG.S) are taking matters into their own hands, bulking up staff to increase patient and physician awareness about testing and building up a gene testing infrastructure that for many community hospitals still does not exist. Bayer executives told Reuters it plans to spend $70 million to increase patient and physician awareness of testing for rare mutations and to encourage regulatory approval of more tests. They expect that budget to expand as Vitrakvi continues to win approval in other countries. Lilly told Reuters the company has signed an agreement with Thermo Fisher Scientific (TMO.N) to develop a companion diagnostic test for its experimental drug, LOXO-292. The deal adds RET mutations - the target of both Lilly’s and Blueprint’s drugs - to Thermo’s Oncomine Dx Target Test, which local pathology labs can use to identify multiple genes linked with non-small cell lung cancer. The agreement is aimed to help identify more lung and thyroid cancer patients who may benefit from the Lilly or Blueprint therapies. The Thermo test is already approved by the U.S. Food and Drug Administration - a key standard for Medicare coverage, the companies said. According to Dr. Brian Alexander, chief medical officer of Roche’s gene testing company Foundation Medicine, only about 15% of U.S. patients with advanced cancers get comprehensive genomic  profiling. Another 25% get single-gene testing, he said, and a large proportion “are not getting any testing at all.”  At MD Anderson, which sees 100,000 new cancer patients a year, only around 10,000 eventually have their tumors sequenced. For a rare few, the tests are lifesaving. Xin Zheng, 47, a mother of three in Michigan who was referred to Reuters by Blueprint, was diagnosed with stage 4 lung cancer in 2016. After failing several treatments, she was out of options. Her husband, Zhigang Wei, asked for genetic sequencing, and the test turned up a RET mutation. After contacting multiple lung cancer experts, Zhigang found an early-stage clinical trial treating patients with Blueprint’s experimental drug, BLU-677. Now, Xin is nearly back to normal. “My wife is lucky,” he said, adding her quality of life is much better and she has hope for the future. Finding patients with such rare mutations is like “looking for the needle in the haystack,” said Stefan Oelrich, head of pharmaceuticals at Bayer. Dr. David Hyman of Memorial Sloan Kettering Cancer Center, who tested Vitrakvi in clinical trials, said making these tests the norm for advanced cancer patients will require a huge shift in the way oncology is practiced. “It’s painful to know there are patients out there with these alterations who are dying without knowing about it and without getting any treatments,” he said. For Bayer’s Vitrakvi and Roche’s Rozlytrek, along with similar drugs in development, genomic testing is critical to finding patients who can benefit from them. Cancer patients and drug companies alike got a boost last year when the federal Medicare health program for the elderly and disabled said it would cover FDA-approved tests for advanced cancer patients that can identify hundreds of genetic mutations at once. A Medicare endorsement is generally followed by widespread coverage decisions by private insurers. But the final regulations dropped a requirement that testmakers prove the tests are cost-effective and improve patient care. That created an “evidence gap” that has allowed some insurers, also known as third-party payers, to withhold coverage or demand more proof that they benefit patients, said Jeff Schreier of Diaceutics PLC (DXRX.L), a data analytics company that works with drugmakers to improve diagnostic testing. “More payers are coming around, but it’s slow,” he said. The most recent coverage policy from CVS Health Corp’s (CVS.N) Aetna approves many single-gene tests for specific cancers, but still largely considers multi-gene tests experimental. Anthem Inc’s (ANTM.N) policy limits testing to “medically necessary” use and states there’s “insufficient published evidence” to support widespread testing. And while Foundation Medicine’s and Thermo Fisher’s tests are getting reimbursed from Medicare, many hospitals such as MD Anderson, which have developed their own tests, are not guaranteed payment. “Reimbursement is still a driving force,” MD Anderson’s Kenna Shaw said of genomic testing, which costs an average of $5,000 per patient globally. Lilly bought Loxo in January for $8 billion to profit from its targeted drugs in early-stage development. Bayer secured the rights to Loxo’s two leading compounds in a 2017 alliance. Dr. Anthony Sireci, Loxo’s senior medical director, said the company has been working to “democratize” testing in the United States by increasing its use in local pathology labs, where most cancer testing has traditionally been done. The Thermo Fisher agreement will support those goals and expand patients’ access to “high-quality genomic testing,” he said. Bayer has hired diagnostic experts to help its medical and sales staff assess the barriers to genomic testing and ensure that local pathology labs are including the genetic alterations targeted by its drugs when they profile tumors, the company’s oncology strategic business chief Robert LaCaze said in an interview. Bayer also launched a public awareness campaign called “Test Your Cancer” that urges patients to ask their doctors about genomic cancer testing. The company is working with testing providers to ensure test reports are easy to understand. Blueprint, which has six genomically-targeted drugs in development, told Reuters it plans to hire six diagnostics experts to increase awareness of the mutations their drugs target, especially in community medical practices, where 70% of cancers are treated. Bayer sees signs of progress. Based on internal data, the company estimates average sequencing rates across tumors neared 30% last year, and the company saw a two-fold increase in the number of labs offering tests that carry the mutation targeted by Vitrakvi. Bayer has not released sales figures for Vitrakvi. Asked for an update in the most recent earnings call in July, Bayer’s Oelrich said uptake is going “according to plan,” but declined to say how many patients are using the drug. LaCaze said with very rare cancers like the ones Vitrakvi targets, sales growth is “something that will build over time.” Claim: Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'.
Example Output:
In the halls of MD Anderson Cancer Center, the drug Vitrakvi is known for having a “Lazarus effect” in some patients because it can reverse late-stage cancer that has defied all other treatment options.